- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Pfizer acquired Biohaven's migraine business, requiring FDA approval for the resulting drug launch.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer acquired Biohaven's migraine business, requiring FDA approval for the resulting drug launch.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- FDA accepted Pfizer's New Drug Application (NDA) for vepdegestrant, supporting the company's growth trajectory.Sub-event
Pfizer acquired Biohaven's migraine business, necessitating FDA approval for the drug launch.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Generic medicine services are seeking approval for launch from the FDA.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
Coverage
Newest first; wire copies grouped- BioPharma DiveBiohaven’s rare disease drug is ‘ready to ship on Day 1’ following FDA approval This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily